Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

WORLD VIEW BLOG: Austerity-driven off-label prescribing must stop

This article was originally published in Scrip

Executive Summary

It is worrying to observe how countries in Europe are increasingly challenging harmonized EU rules on authorizing drugs for the sake of cutting costs in their national health systems. It seems that in particular, off-label prescribing is now seen as a good way to make savings in healthcare spending. This hasn't always been the case. Off-label prescribing was largely limited to cases where no authorized treatment existed. In times of austerity, however, this has clearly changed.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC021969

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel